In 2013, Acquisitions, Clinical and Dx Applications Defined Bioinformatics Market | GenomeWeb

Because most pure-play bioinformatics companies aren't publicly traded, the sector doesn’t have the financial barometer that things like quarterly earnings reports provide, making it somewhat challenging to gauge growth and speculate about future gains.

However, indicators such as intellectual property acquisitions, venture capital investments, and newly birthed businesses hint at the market’s perceived value and suggest that investors are optimistic about its prospects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.